Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UT-231B in Hepatitis C
NCT00069511Phase 2Unknown
- Sponsor
- United Therapeutics Corporation
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of UT-231B in hepatitis C (HCV) (5 arms), sponsored by United Therapeutics Corporation. Primary endpoint: Reduction in Hepatitis C viral load at 12 weeks. Status: unknown.
02
Drugs
UT-231B
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00069511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00069511.